CVRx Q2 revenue beats estimates, outlook cut on sales force, payer challenges

Cvrx

06/08/2026 21:48

Overview
US medical device maker's Q2 revenue rose 16% yr/yr, beating analyst expectations
Q2 net loss narrowed from prior year period
Company lowered full-year revenue outlook citing sales force and challenges with a large payer

Outlook
CVRx expects full-year 2026 revenue between $58 mln and $60 mln
Company sees Q3 2026 revenue between $13.5 mln and $14.5 mln
CVRx now expects 2026 gross margin of 86%-87% and operating expenses of $99 mln-$101 mln

Result Drivers
US GROWTH - Revenue growth driven by expansion into new US sales territories, new accounts, and increased awareness of Barostim therapy
REIMBURSEMENT PROGRESS - New Medicare Advantage coverage policy from Humana supported reimbursement for Barostim therapy
EUROPEAN DECLINE - European revenue fell due to lower unit sales

Company press release: ID:nGNX4Dbccv

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$15.71 mln
$15.55 mln (7 Analysts)
Q2 Loss Per Share
 
$0.53
 
Q2 Net Loss
 
$14.04 mln
 
Q2 Gross Profit
 
$13.72 mln
 
Q2 Loss Per Basic Share
 
$0.53
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for CVRx, Inc. is $12.00, about 115.1% above its August 5 closing price of $5.58

Reuters Recommended Reads
Aug 3 - Inspire Medical Q2 revenue falls less than expected
Aug 5 - Nyxoah Q2 revenue surges on U.S. growth, but margins drop
Aug 5 - Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)